Molecular Partners Stock Forecast
NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MOLN analyst consensus
Consensus (5 analysts)
none
Avg. price target
$10.37+172.18%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Molecular Partners (2026-10-08), 4 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $10.37, with a high estimate of $16.39 and a low estimate of $3.64. The average target implies upside of 172.2% from the current price of $3.81.
The spread between the highest and lowest targets is 350.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MOLN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 80% |
| Hold | 1 | 20% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.64 | -4.46% |
| Average target | $10.37 | +172.18% |
| High target | $16.39 | +330.18% |